Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3928/23258160-20250220-01 | DOI Listing |
Ophthalmic Surg Lasers Imaging Retina
February 2025
Ophthalmic Surg Lasers Imaging Retina
January 2025
Ophthalmic Surg Lasers Imaging Retina
December 2024
JCO SEQUOIA (ClinicalTrials.gov identifier: NCT03336333) is a phase III, randomized, open-label trial that compared the oral Bruton tyrosine kinase inhibitor zanubrutinib to bendamustine plus rituximab (BR) in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The initial prespecified analysis (median follow-up, 26.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!